For R/R ALL and NHL, bispecific CD19/CD20 and CD19/CD22 CARs are currently in clinical trials but preliminary results demonstrated good efficacy with favorable safety profile [86,87,88,89]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.